{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:43Z","timestamp":1794565543603,"version":"4.9.1"},"reference-count":83,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":129,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA214278"],"award-info":[{"award-number":["P01CA214278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012200","name":"Laffey-McHugh Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Current understanding of lymphoma cell-intrinsic mechanisms of relapse following chimeric antigen receptor (CAR) T-cell treatment of diffuse large B-cell lymphoma (DLBCL) include antigen loss and apoptosis resistance. Herein, CD19 CAR T-cell response and resistance were modeled, and it was identified that treatment-na\u00efve CD19 expression does not correlate with CAR T-cell sensitivity, but resistance is frequently accompanied by reversible downregulation of CD19 that once restored is not paralleled with restored sensitivity to CAR T cell\u2013mediated killing. Profiling a suite of DLBCL cell lines to CD19 CAR T-cell sensitivity reveals that DLBCL cells become nonresponsive to CAR T cell\u2013killing, including to alternative antigen targeting of CD20 or CD22. Leveraging these resistant models, we identified gene signatures present in the CAR T cell\u2013resistant DLBCL cell lines that correlate with patient response to CTL019 in two independent clinical trials. Finally, we show that combination strategies to overcome this resistance, including up-front dual-antigen targeting and combined treatment with an Mcl-1 inhibitor, improve CAR T-cell responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We demonstrate that DLBCL cells surviving CD19 CAR T-cell treatment develop a resistance phenotype with a \u201cresistance signature\u201d predictive of clinical CAR T-cell response, mediating cross-resistance between CAR T cells targeting different antigens. Our findings suggest that up-front dual-antigen targeting and combination therapies could improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0176","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T20:28:42Z","timestamp":1751056122000},"page":"580-601","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-1648","authenticated-orcid":false,"given":"Fabiana","family":"L\u00fc\u00f6nd","sequence":"first","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2442-7511","authenticated-orcid":false,"given":"Jeanne","family":"Whalen","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-6429","authenticated-orcid":false,"given":"Youngchul","family":"Song","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4695-9906","authenticated-orcid":false,"given":"Kalyn","family":"Schriefer","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5446-9034","authenticated-orcid":false,"given":"Rick","family":"Newcombe","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6448-8874","authenticated-orcid":false,"given":"Elena J.","family":"Orlando","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-7313","authenticated-orcid":false,"given":"Sarah M.","family":"Choi","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"3Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"4Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8993","authenticated-orcid":false,"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[{"name":"2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"5Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"6Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"7Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"8Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"3Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-832X","authenticated-orcid":false,"given":"Jennifer L.","family":"Brogdon","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7807-9586","authenticated-orcid":false,"given":"Matthew J.","family":"Niederst","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-6711","authenticated-orcid":false,"given":"Louise M.","family":"Treanor","sequence":"additional","affiliation":[{"name":"1Novartis Biomedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"2025110303123342300_bib1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"2025110303123342300_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2025110303123342300_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"2025110303123342300_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2025110303123342300_bib5","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025110303123342300_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"key":"2025110303123342300_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025110303123342300_bib8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2025110303123342300_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"2025110303123342300_bib10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2025110303123342300_bib11","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2025110303123342300_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-all patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"2025110303123342300_bib13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"2025110303123342300_bib14","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1038\/s41467-022-31035-7","article-title":"Antigen glycosylation regulates efficacy of CAR T cells targeting CD19","volume":"13","author":"Heard","year":"2022","journal-title":"Nat Commun"},{"key":"2025110303123342300_bib15","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"2025110303123342300_bib16","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"2025110303123342300_bib17","doi-asserted-by":"crossref","first-page":"e002352","DOI":"10.1136\/jitc-2021-002352","article-title":"Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro","volume":"9","author":"Ledererova","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025110303123342300_bib18","doi-asserted-by":"crossref","first-page":"e001150","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025110303123342300_bib19","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020005123","article-title":"Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"2025110303123342300_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/PAS.0000000000001834","article-title":"Resistance of B-cell lymphomas to CAR T-cell therapy is associated with genomic tumor changes which can result in transdifferentiation","volume":"46","author":"Laurent","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"2025110303123342300_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"2025110303123342300_bib22","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"key":"2025110303123342300_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.18724","article-title":"How I treat refractory\/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells","volume":"201","author":"Nagler","year":"2023","journal-title":"Br J Haematol"},{"key":"2025110303123342300_bib24","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"2025110303123342300_bib25","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/bjh.18333","article-title":"Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies","volume":"198","author":"Mian","year":"2022","journal-title":"Br J Haematol"},{"key":"2025110303123342300_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbmt.2017.12.644","article-title":"Axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive Non-Hodgkin Lymphoma (NHL): long-term follow-up of the pivotal Zuma-1 trial","volume":"24","author":"Neelapu","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"2025110303123342300_bib27","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.modpat.2023.100256","article-title":"Detection of aberrant CD58 expression in a wide spectrum of lymphoma subtypes: implications for treatment resistance","volume":"36","author":"Younes","year":"2023","journal-title":"Mod Pathol"},{"key":"2025110303123342300_bib28","doi-asserted-by":"crossref","first-page":"e159402","DOI":"10.1172\/JCI159402","article-title":"Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses","volume":"132","author":"Romain","year":"2022","journal-title":"J Clin Invest"},{"key":"2025110303123342300_bib29","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1182\/bloodadvances.2022007891","article-title":"CD58 loss in tumor cells confers functional impairment of CAR T cells","volume":"6","author":"Yan","year":"2022","journal-title":"Blood Adv"},{"key":"2025110303123342300_bib30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"key":"2025110303123342300_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"key":"2025110303123342300_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov"},{"key":"2025110303123342300_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/cgt.2013.35","article-title":"Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy","volume":"20","author":"Karlsson","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"2025110303123342300_bib34","doi-asserted-by":"crossref","first-page":"608167","DOI":"10.3389\/fimmu.2020.608167","article-title":"Pre-sensitization of malignant B cells through Venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"2025110303123342300_bib35","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","article-title":"Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"2025110303123342300_bib36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/cancers10060200","article-title":"Overcoming resistance of human non-hodgkin's lymphoma to CD19-CAR CTL therapy by Celecoxib and histone deacetylase inhibitors","volume":"10","author":"Torres-Collado","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025110303123342300_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2025110303123342300_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2025110303123342300_bib39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"2025110303123342300_bib40","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1158\/1078-0432.CCR-06-2891","article-title":"Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma","volume":"13","author":"Cillessen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025110303123342300_bib41","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025110303123342300_bib42","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1158\/2159-8290.CD-24-1071","article-title":"Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with relapsed\/refractory LBCL","volume":"15","author":"Su","year":"2025","journal-title":"Cancer Discov"},{"key":"2025110303123342300_bib43","doi-asserted-by":"crossref","first-page":"114421","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: a clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"2025110303123342300_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13000-019-0880-7","article-title":"Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience","volume":"14","author":"Hu","year":"2019","journal-title":"Diagn Pathol"},{"key":"2025110303123342300_bib45","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1182\/bloodadvances.2021006348","article-title":"The T\u0391p63\/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia","volume":"6","author":"Laidou","year":"2022","journal-title":"Blood Adv"},{"key":"2025110303123342300_bib46","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.4161\/cc.7.13.6234","article-title":"KLF13 influences multiple stages of both B and T cell development","volume":"7","author":"Outram","year":"2008","journal-title":"Cell Cycle"},{"key":"2025110303123342300_bib47","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoc Bioinformatics"},{"key":"2025110303123342300_bib48","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.18632\/oncotarget.23425","article-title":"Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development","volume":"9","author":"Gu","year":"2018","journal-title":"Oncotarget"},{"key":"2025110303123342300_bib49","doi-asserted-by":"crossref","first-page":"e2021175118","DOI":"10.1073\/pnas.2021175118","article-title":"Hexokinases inhibit death receptor-dependent apoptosis on the mitochondria","volume":"118","author":"Lauterwasser","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025110303123342300_bib50","doi-asserted-by":"crossref","first-page":"101391","DOI":"10.1016\/j.tranon.2022.101391","article-title":"TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway","volume":"19","author":"Cai","year":"2022","journal-title":"Transl Oncol"},{"key":"2025110303123342300_bib51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/0008-5472.CAN-23-1459","article-title":"AXL\/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer","volume":"84","author":"Marquez-Palencia","year":"2024","journal-title":"Cancer Res"},{"key":"2025110303123342300_bib52","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1038\/cddis.2013.186","article-title":"B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1","volume":"4","author":"Zhou","year":"2013","journal-title":"Cell Death Dis"},{"key":"2025110303123342300_bib53","first-page":"3662","article-title":"COA3 overexpression promotes non-small cell lung cancer metastasis by reprogramming glucose metabolism","volume":"12","author":"Lin","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2025110303123342300_bib54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2021015008","article-title":"Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"key":"2025110303123342300_bib55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","article-title":"Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture","volume":"589","author":"Yusufova","year":"2021","journal-title":"Nature"},{"key":"2025110303123342300_bib56","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41375-024-02349-w","article-title":"Tumor evolution analysis uncovered immune-escape related mutations in relapse of diffuse large B-cell lymphoma","volume":"38","author":"Han","year":"2024","journal-title":"Leukemia"},{"key":"2025110303123342300_bib57","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"key":"2025110303123342300_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"key":"2025110303123342300_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood-2021-145764","article-title":"Impact of molecular features of diffuse large B-cell lymphoma on treatment outcomes with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy","volume":"138","author":"Hill","year":"2021","journal-title":"Blood"},{"key":"2025110303123342300_bib60","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"2025110303123342300_bib61","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"key":"2025110303123342300_bib62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1535-7163.MCT-21-0506","article-title":"Exploration of tumor biopsy gene signatures to understand the role of the tumor microenvironment in outcomes to lisocabtagene maraleucel","volume":"22","author":"Olson","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2025110303123342300_bib63","doi-asserted-by":"crossref","first-page":"1519473","DOI":"10.3389\/fonc.2025.1519473","article-title":"Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)","volume":"15","author":"Tian","year":"2025","journal-title":"Front Oncol"},{"key":"2025110303123342300_bib64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ijc.2910230206","article-title":"Characterization of a leukemic cell line of the pre-B phenotype","volume":"23","author":"Hurwitz","year":"1979","journal-title":"Int J Cancer"},{"key":"2025110303123342300_bib65","first-page":"221","article-title":"A new non-Hodgkin\u2019s B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21)","volume":"5","author":"Kluin-Nelemans","year":"1991","journal-title":"Leukemia"},{"key":"2025110303123342300_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk Res"},{"key":"2025110303123342300_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/10428199509059672","article-title":"p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin\u2019s lymphoma cell lines","volume":"19","author":"Chang","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"2025110303123342300_bib68","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V69.5.1307.1307","article-title":"The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor","volume":"69","author":"Tweeddale","year":"1987","journal-title":"Blood"},{"key":"2025110303123342300_bib69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.1994.tb04726.x","article-title":"The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7","volume":"86","author":"Greil","year":"1994","journal-title":"Br J Haematol"},{"key":"2025110303123342300_bib70","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1080\/1042819021000032917","article-title":"A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma","volume":"43","author":"Amini","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2025110303123342300_bib71","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1080\/10428190701636443","article-title":"Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN","volume":"48","author":"Fridberg","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2025110303123342300_bib72","first-page":"1305","article-title":"Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts","volume":"4","author":"Al-Katib","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2025110303123342300_bib73","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.leukres.2006.05.003","article-title":"Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors","volume":"30","author":"Tohda","year":"2006","journal-title":"Leuk Res"},{"key":"2025110303123342300_bib74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood.V75.3.709.709","article-title":"A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations","volume":"75","author":"Dyer","year":"1990","journal-title":"Blood"},{"key":"2025110303123342300_bib75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nprot.2012.016","article-title":"Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks","volume":"7","author":"Trapnell","year":"2012","journal-title":"Nat Protoc"},{"key":"2025110303123342300_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2025110303123342300_bib77","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"2025110303123342300_bib78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025110303123342300_bib79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeqa Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"2025110303123342300_bib80","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"key":"2025110303123342300_bib81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2025110303123342300_bib82","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"2025110303123342300_bib83","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0176\/3627377\/bcd-24-0176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0176\/3658900\/bcd-24-0176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/580\/3663444\/bcd-24-0176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/580\/3663444\/bcd-24-0176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:12:52Z","timestamp":1762157572000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/6\/580\/766819\/DLBCL-Cells-Emerge-after-CD19-CAR-T-Cells-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":83,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,27]]},"published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0176","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.30515970","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30515964","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30515961","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30515967","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8125935","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}